Changes in Asthma Maintenance Therapy Prescribing Patterns Following the 2006 Long-Acting β-Agonist FDA Drug Warning

Abstract Purpose The US Food and Drug Administration issued a boxed warning on all products containing a long-acting β-agonist (LABA) in March 2006, after the findings from a trial suggested an increased risk for death in patients treated with salmeterol monotherapy. Almost nothing is known about th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2017-04, Vol.39 (4), p.697-701
Hauptverfasser:	Winter, Jonathan D., MD, Reetz, Matthew R., DO, Kerns, J. William, MD, Winter, Katherine M., CFNP, Sabo, Roy T., PhD, Krugman, Scott D., MD, MS
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Adrenal Cortex Hormones - therapeutic use Adrenergic beta-Agonists - therapeutic use Adult Adults African Americans Age Asthma Asthma - drug therapy Budesonide Communication Computer programs Consumers Corticoids Corticosteroids Data processing Demographic variables Demographics Diagnosis Drug dosages Drug Labeling Drug therapy Drug Therapy, Combination Drugs Fatalities Female Fluticasone Formoterol Government programs Greening Health care Health risks Humans Hypersensitivity Information dissemination Internal Medicine LABA Lungs Maintenance Male Medicaid Medical Education Medical personnel Patients Pharmacology Populations Practice Patterns, Physicians' - trends prescribing patterns Prescription drugs Product safety Protocol (computers) Quality of life Respiratory function Retrospective Studies Risk taking Safety Salbutamol Salmeterol Seasonal variations Software Statistical analysis Surveillance Theophylline Therapy United States United States Food and Drug Administration Utilization Warning Winter
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!